JNJ looks promising for a breakout. With MRNA vaccines facing increased scrutiny in Europe, JNJ may benefit potentially.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
